{{위키데이터 속성 추적}}
{{Drugbox
| Verifiedfields = verified
| Watchedfields = verified
| verifiedrevid = 457636058
| IUPAC_name = 2-[(1''R'',6''R'')-6-Isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
| image = Cannabidiol.svg
| width = 225px
| image2 = CBD-3D-balls.png
| width2 = 250px

<!--Clinical data-->
| tradename = [[:en:Sativex]] (with {{abbrlink|THC|tetrahydrocannabinol}}), [[:en:Epidiolex]]
| Drugs.com = {{drugs.com|international|cannabidiol}}
| legal_US = Schedule I (except Epidiolex, Schedule V)
| legal_UK = POM
| legal_UK_comment = or Dietary Supplement
| legal_AU = S4
| routes_of_administration = [[:en:Route of administration#Inhalation|Inhalation]] ([[흡연]], [[전자 담배]]), [[:en:buccal administration|buccal]] ([[:en:aerosol spray]]), [[:en:oral administration|oral]] ([[용액]])<ref name="SativexLabel">{{웹 인용|url=https://omr.bayer.ca/omr/online/sativex-pm-en.pdf|title=Sativex (Cannabidiol/Tetrahydrocannabinol) Bayer Label|website=bayer.ca|accessdate=28 June 2018|archive-date=2021-01-16|archive-url=https://web.archive.org/web/20210116114657/https://omr.bayer.ca/omr/online/sativex-pm-en.pdf|url-status=dead}}</ref><ref name="EpidiolexLabel">{{웹 인용|url=https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf|title=Epidiolex (Cannabidiol) FDA Label|website=fda.gov|accessdate=28 June 2018}} For label updates see [https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=210365 FDA index page for NDA 210365]</ref>
| class = [[카나비노이드]]

<!--Pharmacokinetic data-->
| bioavailability = • [[:en:Oral administration|Oral]]: 13–19%<ref name = Mechoulam2002>{{저널 인용| vauthors = Mechoulam R, Parker LA, Gallily R | title = Cannabidiol: an overview of some pharmacological aspects | journal = Journal of Clinical Pharmacology | volume = 42 | issue = 11 Suppl | pages = 11S–19S | date = November 2002 | pmid = 12412831 | doi = 10.1002/j.1552-4604.2002.tb05998.x }}</ref><br />• [[:en:Inhalation|Inhaled]]: 31% (11–45%)<ref name=Scuderi2009>{{저널 인용| vauthors = Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G | title = Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders | journal = Phytotherapy Research | volume = 23 | issue = 5 | pages = 597–602 | date = May 2009 | pmid = 18844286 | doi = 10.1002/ptr.2625 | type = Review }}</ref>
| protein_bound = 
| metabolism = 
| metabolites = 
| elimination_half-life = 18–32 hours<ref name="devinsky">{{저널 인용|last1=Devinsky |first1=Orrin |last2=Cilio |first2=Maria Roberta |last3=Cross |first3=Helen |last4=Fernandez-Ruiz |first4=Javier |last5=French |first5=Jacqueline |last6=Hill |first6=Charlotte |last7=Katz |first7=Russell |last8=Di Marzo |first8=Vincenzo |last9=Jutras-Aswad |first9=Didier |last10=Notcutt |first10=William George |last11=Martinez-Orgado |first11=Jose |last12=Robson |first12=Philip J. |last13=Rohrback |first13=Brian G. |last14=Thiele |first14=Elizabeth |last15=Whalley |first15=Benjamin |last16=Friedman |first16=Daniel |title=Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders |journal=Epilepsia |date=22 May 2014 |volume=55 |issue=6 |pages=791–802 |doi=10.1111/epi.12631|pmc=4707667|pmid=24854329}}</ref>
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 13956-29-1
| ATC_prefix = N03
| ATC_suffix = AX24
| PubChem = 644019
| IUPHAR_ligand = 4150
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 69478
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB09061
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 24593618
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 19GBJ60SN5
| KEGG = D10915
| synonyms = CBD, cannabidiolum, (−)-cannabidiol<ref>https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:69478</ref>

<!--Chemical data-->
| C=21 | H=30 | O=2
| molecular_weight = 314.464 g/mol
| SMILES = Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h9,12-13,17-18,22-23H,2,5-8,10-11H2,1,3-4H3/t17-,18+/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = ZTGXAWYVTLUPDT-ZWKOTPCHSA-N

<!--Physical data-->
| melting_point = 66
| boiling_point = 
}}

'''칸나비디올'''({{llang|en|cannabidiol, '''CBD'''}})은 1940년에 발견된 [[카나비노이드|식물칸나비노이드]]이다. [[삼속]] 식물에서 식별된 113개의 [[카나비노이드]] 가운데 하나로서, 식물 [[추출물]] 가운데 최대 40%를 차지한다.<ref name="pmid23108553" /> 2018년 기준으로, 칸나비디올의 예비 [[임상 연구]]에는 [[불안]], [[인식]], [[운동장애]], [[통증]]의 연구가 포함되었다.<ref name=Boggs/>

칸나비디올은 여러 방법으로 인체에 투여할 수 있으며, 여기에는 카나비스(대마초) 연기나 증기를 [[에어로졸 스프레이]]로 턱이나 입쪽을 향해 투여하는 것이 포함된다. 활성 성분으로서 CBS만을 포함하는([[테트라히드로칸나비놀]] [THC] 또는 [[테르펜]] 없음) 식물의 CBD 대마 추출 기름, 캡슐, 말린 카나비, 처방 [[용액]]으로 구성되는 '''CBD 오일'''(CBD oil)로 제공될 수 있다.<ref name="EpidiolexLabel" /> CBD는 THC와 동일한 [[향정신성의약품|정신작용]]을 보이지 않으며,<ref name="pmid28232276" /><ref name="Iseger2015">{{저널 인용| vauthors = Iseger TA, Bossong MG | title = A systematic review of the antipsychotic properties of cannabidiol in humans | journal = Schizophrenia Research | volume = 162 | issue = 1–3 | pages = 153–61 | date = March 2015 | pmid = 25667194 | doi = 10.1016/j.schres.2015.01.033 }}</ref> THC의 동작에 영향을 줄 수 있다.<ref name="pmid23108553">{{저널 인용| vauthors = Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimarães FS | title = Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders | journal = Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences | volume = 367 | issue = 1607 | pages = 3364–78 | date = December 2012 | pmid = 23108553 | pmc = 3481531 | doi = 10.1098/rstb.2011.0389 | type = Review }}</ref><ref name="Boggs">{{저널 인용| last=Boggs | first=Douglas L | last2=Nguyen | first2=Jacques D | last3=Morgenson | first3=Daralyn | last4=Taffe | first4=Michael A | last5=Ranganathan | first5=Mohini | title=Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol | journal=Neuropsychopharmacology| volume=43 | issue=1 | date=6 September 2017 | issn=0893-133X | pmid=28875990 | pmc=5719112 | doi=10.1038/npp.2017.209 | pages=142–154}}</ref><ref name="pmid28232276">{{저널 인용| vauthors = Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M | title = Cannabidiol: State of the art and new challenges for therapeutic applications | journal = Pharmacol. Ther. | volume = 175 | issue = | pages = 133–150 | date = July 2017 | pmid = 28232276 | doi = 10.1016/j.pharmthera.2017.02.041 }}</ref><ref name="pmid26836472">{{저널 인용| vauthors = Aizpurua-Olaizola O, Soydaner U, Öztürk E, Schibano D, Simsir Y, Navarro P, Etxebarria N, Usobiaga A | title = Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes | journal = Journal of Natural Products | volume = 79 | issue = 2 | pages = 324–31 | date = February 2016 | pmid = 26836472 | doi = 10.1021/acs.jnatprod.5b00949 }}</ref> [[인 비트로]] 연구에 따르면 CBD가 [[칸나비노이드 수용체]], 기타 [[신경전달물질수용체]]를 포함, 각기 다른 생물학적 대상과 상호 작용할 수 있다는 의견이 있으나,<ref name="pmid28232276" /><ref name="pmid29941868">{{저널 인용| vauthors = Laun AS, Shrader SH, Brown KJ, Song ZH | title = GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol | journal = Acta Pharmacol. Sin. | volume = 40| issue = 3| pages = 300–308| date = June 2018 | pmid = 29941868 | doi = 10.1038/s41401-018-0031-9 }}</ref> 2018년 기준으로 생물학적 영향에 대한 동작 구조는 명확히 밝혀져 있지 않은 상황이다.<ref name=Boggs/><ref name="pmid28232276" />

미국에서 칸나비디올의 약제인 [[에피디올렉스]]라는 약은 [[뇌전증]] 질환 치료를 위해 [[미국 식품의약국]]에 의해 승인되어 있다.<ref name="fda18">{{웹 인용|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611046.htm|title=FDA approves first drug {{sic|comprised |hide=y|of}} an active ingredient derived from marijuana to treat rare, severe forms of epilepsy|publisher=US Food and Drug Administration|date=25 June 2018|accessdate=25 June 2018}}</ref> 이 약물의 장기간 부작용에는 [[졸림]], [[신경성 식욕 부진증|식욕 부진]], [[설사]], [[피로]], 불안, [[무기력]], [[수면 장애]] 등이 포함된다.<ref name="EpidiolexLabel" />

미국의 [[마약단속국]]은 에피디올렉스를 [[:en:Controlled Substances Act#Schedule V controlled substances|스케줄 V]] 분류로 할당해 놓은 반면, 에피디올렉스에 속하지 않는 CBD는 모든 용도에 금지된 [[:en:Controlled Substances Act#Schedule I controlled substances|스케줄 I]] 약물로 등재되어 있다.<ref name="CNBC">{{뉴스 인용| url = https://www.cnbc.com/2018/09/27/dea-schedules-epidiolex-allowing-gw-pharma-to-start-selling-the-drug.html | title = DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market | publisher = CNBC | date = September 27, 2018}}</ref> 칸나비디올은 [[유엔]] 약물 통제 조약에 기입되어 있지 않으며 2018년 [[세계보건기구]]는 미기입 유지를 권고하였다.<ref name="Angell UN">{{뉴스 인용|last1=Angell |first1=Tom | name-list-format = vanc |title=UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law |url=https://www.marijuanamoment.net/un-launches-first-ever-full-review-of-marijuanas-status-under-international-law/ |accessdate=1 November 2018 |work=Marijuana Moment |date=13 August 2018}}</ref>

== 화학 ==
=== 생합성 ===
[[파일:Cannabidiol and THC biosynthesis.svg|upright=1.3|섬네일|왼쪽|칸나비디올과 THC 생합성<ref>{{저널 인용| vauthors = Taura F, Sirikantaramas S, Shoyama Y, Yoshikai K, Shoyama Y, Morimoto S | title = Cannabidiolic-acid synthase, the chemotype-determining enzyme in the fiber-type Cannabis sativa | journal = FEBS Letters | volume = 581 | issue = 16 | pages = 2929–34 | date = June 2007 | pmid = 17544411 | doi = 10.1016/j.febslet.2007.05.043 }}</ref>]]

{{-}}
== 같이 보기 ==
* [[삼씨기름]]

== 각주 ==
{{각주}}

== 추가 문헌 ==
{{참고 자료 시작}}
* {{뉴스 인용|title=Why Is CBD Everywhere? |last1=Williams |first1=Alex |work=[[뉴욕 타임스]] |date=2018-10-27 |url=https://www.nytimes.com/2018/10/27/style/cbd-benefits.html |issn=0362-4331 |df=mdy-all }}
{{참고 자료 끝}}

{{전거 통제}}

[[분류:진통제]]
[[분류:항염증제]]
[[분류:항경련제]]
[[분류:카나비노이드]]
[[분류:사이클로헥센]]
[[분류:5-HT1A 작용제]]
[[분류:레조르시놀]]
[[분류:천연 페놀류]]